EANS-News: november Aktiengesellschaft
Announce Asset Deal with MICROBIONIX -
affiliated companies PROGEN/Multimetrix take over personnel and laboratory
equipment from MICROBIONIX
Cologne, Heidelberg, Regensburg (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Mergers - Acquisitions - Takeovers
Effective January 1, 2011 PROGEN Biotechnik GmbH, Heidelberg, and Multimetrix GmbH, Regensburg, both affiliated companyies of the november AG, are taking over personnel and laboratory equipment of MICROBIONIX GmbH as part of an asset deal. Thus, PROGEN/Multimetrix are broadening their product range in the area of the Luminex® technology by services hitherto offered by MICROBIONIX, including testing services, bead coupling and sample testing on customer demand and make available existing knowhow to implement this extended offering. (www.multimetrix.com/en/service/testservice.html) The association of PROGEN and Multimetrix will strengthen the competence in the multiplex technology, and the segment of customized test services with an extended panel of parameters for sample testing is significantly expanded. With the Luminex® technology, even in small sample volumes several analytes can be detected fast and simultaneously. Flexible parameter panels can be used for complex analysis of multiple preclinical, clinical and research issues or epidemiological studies in fields like e.g. infectious diseases. The november AG expects that this takeover generates a considerable increase in competence which will have a further significant positive impact on sales in the segment of multiplex technology based on the Luminex® platform.
About Luminex® Technology The xMAP® (Multi Analyte Profiling) technology developed by Luminex® (www.luminexcorp.com) is an innovative assay platform for a large range of applications. With this technology it is possible to simultaneously test 100 parameters in one test run. Thus, the user saves time and sample material. The technology is based on microscopically small polystyrene beads which are coated with antigens e.g. against different infectious diseases. The automated process allows the beads to identify up to 100 different analytes from one sample. This very sensitive and specific detection enables fast screening tests of many different samples as well as a differential sample analysis.
About november AG / PROGEN Biotechnik GmbH / Multimetrix GmbH november AG, Cologne is an investment and holding company, listed in the prime standard of the regulated market of the German stock exchange (Deutsche Börse), with special focus on medical technology, biotechnology, and environmental technologies and 100% shareholder of PROGEN Biotechnik GmbH (www.progen.de). PROGEN Biotechnik GmbH, Heidelberg, is manufacturer of in vitro diagnostics (borrelia, hanta virus, FSME) and research reagents (antibodies, polypeptides, AAV, hyperphage, www.yperphage.com), certified to DIN EN ISO 13485:2007, as well as for the production of multiplex assays for the Luminex® platform. PROGEN is member of the VDGH (German Association of Diagnostic Manufacturers) and major shareholder of Multimetrix GmbH, Regensburg.
end of announcement euro adhoc
Further inquiry note:
Dr. Dirk Zurek
CEO
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de
Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade